(Incorporated in Delaware)

We are a Phase 2B/Phase 3 biotech advancing three late-stage cardiovascular therapies in indications for which no approved therapies currently exist:

*Danicamtiv – An investigational oral cardiac atrial and ventricular myosin activator to treat genetic dilated cardiomyopathy (“DCM”) caused by pathogenic variants in myosin heavy chain 7 (“MYH7”) and titin (“TTN”), the most common sarcomeric gene variants – Currently in our KINSHIP-DCM Phase 2B/Phase 3 adaptive randomized placebo-controlled trial – Danicamtiv is designed to restore myosin function and availability, directly targeting the underlying sarcomeric defects in DCM (i.e., impaired muscle contraction, force generation and movement of cardiac muscles). It has been evaluated in 10 completed clinical studies.

*Ataciguat – An investigational oral once-daily soluble guanylate cyclase (“sGC”) activator aimed at slowing the progression of calcific aortic valve stenosis (“CAVS”) in patients with moderate disease – Currenty in our KATALYST-AV Phase 2B clinical trial – Ataciguat targets valvular interstitial cells to slow osteogenic and calcific remodeling, the underlying driver of disease progression in CAVS.

*Tonlamarsen – An investigational liver-directed antisense oligonucleotide (“ASO”) administered once monthly via subcutaneous injection, targeting hepatic angiotensinogen (“AGT”) to manage blood pressure in acute severe hypertension (“ASH”) post-hospitalization – Currently in our KARDINAL-ASH Phase 2 trial.

We also run the Prolaio platform, Kardigan’s proprietary data and analytics platform, which includes Class I and Class II U.S. Food and Drug Administration (“FDA”) regulated devices, including 510(k) cleared algorithms. By integrating third-party wearable sensors and Kardigan’s AI-driven analytics, the platform enables automated continuous physiologic data collection from patients in their daily lives outside of the clinic, which we refer to as “real-world data,” at a higher frequency compared to traditional clinical trials.

We use the Prolaio platform to collect and deliver high-frequency, objective patient data continuously throughout a clinical trial in a process we refer to as “longitudinal data collection,” which enables us to optimize trial design, accelerate development, and support the development of novel digital measures that have the potential to be used in a clinical trial (“digital clinical endpoints”). This technology is designed to enhance trial efficiency, patient engagement, and the precision of therapeutic insights.

Our management team includes leaders from MyoKardia, Inc. (“MyoKardia”) with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy.

Cardiovascular disease is the leading cause of death worldwide, yet innovation has lagged due to drug development focused on broad, downstream, symptom-focused approaches despite disease heterogeneity and genetic variability, resulting in incremental advances and lengthy clinical trials. Kardigan is committed to overcoming these challenges by advancing precision medicines that target the fundamental drivers of cardiovascular conditions, aiming to deliver meaningful improvements in patient outcomes.

Note: Net loss is for the 12 months that ended March 31, 2026. The company has no product revenue.

(Note: Kardigan filed its S-1 on May 26, 2026, for its IPO without disclosing the terms. Estimated proceeds are $100 million.)